Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Triple Negative Breast Neoplasms 2Prostatic Neoplasms 1Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma 1Neoplasms 1Melanoma 1Hereditary Sensory and Autonomic Neuropathies 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Alpelisib 4berzosertib 3Fulvestrant 3Everolimus 3parsaclisib 2Topotecan 2NVP-BKM120 2Cetuximab 2talazoparib 1sotorasib 1serabelisib 1ruxolitinib 1duvelisib 1dapagliflozin 1cobimetinib 1ceralasertib 1binimetinib 1avelumab 1Vemurafenib 1SF 1126 1Rituximab 1Paclitaxel 1Oxaliplatin 1Leuprolide 1Leucovorin 1Letrozole 1Irinotecan 1Goserelin 1Fluorouracil 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Hereditary Sensory and Autonomic Neuropathies × ceralasertib × Clear all
NCT04564027 2025-08-29

A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer

AstraZeneca

Phase 2 Completed
54 enrolled 16 charts

Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡